ClinicalTrials.gg

Program

camlipixant

Also written as “BLU-5937”, “Camlipixant” and “BLU-5937 ER”.

In GlaxoSmithKline's pipeline, P2X3 receptor antagonist. Its studies are mostly in Cough · Chronic Cough · Irritable Bowel Syndrome · Dermatitis, Atopic, led by GlaxoSmithKline.

Furthest: phase 3, since Oct 18, 202216 company-led studies, 3 open or runningNext primary completion: Mar 9, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline163 open or runningphase 3since Oct 18, 2022Aug 15, 2018Mar 9, 2027phase 2 · NCT07519395
  • Named in GlaxoSmithKline’s own pipeline as camlipixant GSK5464714, phase 2, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 15, 2018First study: phase 1 study in CoughFirst studyNCT03638180 · 90 enrolled · Canada
  2. Jun 6, 2019Phase 2 study in Chronic CoughNCT03979638 · 68 enrolled · United States, United Kingdom
  3. Dec 9, 20202 phase 2 studiesNCT04678206, NCT04693195
  4. Feb 11, 2022Phase 1 study in HealthyNCT05244759 · 6 enrolled · United Kingdom
  5. Oct 3, 2022Phase 1 study in CoughNCT05570539 · 30 enrolled · United Kingdom
  6. Oct 18, 20222 phase 3 studies in CoughNCT05600777, NCT05599191
  7. Jun 2, 2023Phase 1 study in CoughNCT05899829 · 42 enrolled · Canada
  8. Jul 17, 2023Phase 1 study in CoughNCT05959447 · 45 enrolled · Canada
  9. Nov 27, 2023Phase 1 study in HealthyNCT06179537 · 34 enrolled · United Kingdom
  10. Jan 16, 2024Phase 1 study in CoughNCT06222892 · 32 enrolled · United States
  11. Jul 5, 2024Phase 1 study in CoughNCT06497517 · 14 enrolled · United States
  12. Apr 2, 2026Phase 2 study in Irritable Bowel SyndromeNCT07519395 · 420 planned · United States
  13. Jun 10, 2026Phase 3 study in Chronic CoughNCT07650084 · 75 planned · China
  14. Jun 29, 2026Phase 1 study in CoughNCT07684586 · United Kingdom

Ahead

  1. Mar 9, 2027Primary completion: phase 2 study in Irritable Bowel SyndromeNCT07519395
  2. Aug 27, 2027Primary completion: phase 3 study in Chronic CoughNCT07650084

TargetBeta

“P2X3 receptor antagonist”the company's pipeline, read by Claude · source
“P2X purinoceptor 3 antagonist”ChEMBL 37, by rule

Other programs on P2RX3

ProgramCompanyFurthest phaseStudies
TCR1672Sino Biopharmaceuticalphase 21

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07684586Cough · United Kingdom1WithdrawnAug 27, 20270
NCT07650084Chronic Cough · China3RecruitingAug 27, 202775
NCT07519395Irritable Bowel Syndrome · United States2RecruitingMar 9, 2027420
NCT06497517Cough · United States1CompletedAug 22, 202414
NCT06222892Cough · United States1CompletedDec 17, 202432
NCT06179537Healthy · United Kingdom1CompletedOct 22, 202134
NCT05959447Cough · Canada1CompletedOct 13, 202345
NCT05899829Cough · Canada1CompletedAug 8, 202342
NCT05600777Cough · United States, Australia, Canada and more3Active, not recruitingJun 10, 2026997
NCT05599191Cough · United States, Argentina, Belgium and more3CompletedDec 17, 2025957
NCT05570539Cough · United Kingdom1CompletedMay 2, 202430
NCT05244759Healthy · United Kingdom1CompletedSep 23, 20206
NCT04693195Dermatitis, Atopic · United States, Canada2CompletedOct 4, 2021142
NCT04678206Chronic Cough · United States, Canada, Czechia and more2CompletedOct 21, 2021310
NCT03979638Chronic Cough · United States, United Kingdom2TerminatedApr 23, 202068
NCT03638180Cough · Canada1CompletedOct 25, 201890

How it is read

Names in the registry

  • “BLU-5937”, 8 entries
  • “Camlipixant”, 5 entries
  • “BLU-5937 ER”, 1 entry
  • “GSK5464714- Camlipixant”, 1 entry
  • “[14C]-BLU-5937”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.